The prevalence of chronic hepatitis B virus (HBV) infection in the Philippines, as indicated by hepatitis B surface antigen (HBsAg) Hepatitis B virus (HBV) infection is a major public health problem in the Philippines. The impact of this infection is primarily on the considerable number of disability adjusted life years lost from the chronic sequelae of HBV infection. These include chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), the last of these ranking as one of the leading causes of cancer deaths among Filipino males. A case control study of HCC conducted by Lingao et al showed that the odds ratio for HCC among hepatitis B surface antigen (HBsAg) positive Filipinos was 11.07 (95% CI 4.88 to 25.30), with the crude odds being slightly higher among men than women.1
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Abstract
The prevalence of chronic hepatitis B virus (HBV) infection in the Philippines, as indicated by hepatitis B surface antigen (HBsAg) positivity, ranges from 2% to 16 .5%, with an average of 12% in a study of rural villagers. Although mother to child transmission is a major route of HBV infection, other routes (particularly child to child transmission) play an important part after the first year of life. In a study assessing the feasibility and effectiveness of incorporating hepatitis B vaccine into the national Expanded Programme on Immunisation, the coverage rate for fully immunised 1 year olds ranged from 80-9-84% and anti-HBs seroconversion rates ranged from 72-88%. In countries where HBV is not endemic, high risk groups include commercial sex workers (CSWs) and intravenous drug users (IVDUs), who generally have higher HBsAg positivity rates than the general population. In countries with a high HBV endemicity, carrier rates may be only slightly higher among CSWs, suggesting that other modes of transmission are more important in those regions. CSWs who are also IVDUs are at even greater risk. If HBV infection is to be controlled, innovative education and screening programmes are needed, together with the mass immunisation of neonates now started in many countries around the world.
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Hepatitis B virus (HBV) infection is a major public health problem in the Philippines. The impact of this infection is primarily on the considerable number of disability adjusted life years lost from the chronic sequelae of HBV infection. These include chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), the last of these ranking as one of the leading causes of cancer deaths among Filipino males. A case control study of HCC conducted by Lingao et al showed that the odds ratio for HCC among hepatitis B surface antigen (HBsAg) positive Filipinos was 11.07 (95% CI 4.88 to 25.30) , with the crude odds being slightly higher among men than women.1
The first part of this paper will review the epidemiology of HBV infection in the Philippines, including the major modes of transmission and intervention measures for control in the country. The second part of the paper will focus on the epidemiology of HBV infection among commercial sex workers (CSWs) and intravenous drugs users (IVDUs). These two risk groups are currently not the major focus of interventions in developing countries like the Philippines, but they none the less warrant attention in both HBV endemic and non-endemic countries if better control and, eventually, eradication are to be achieved. Recommendations for control in the Philippines and for these two risk groups are also made. Table I shows the different hepatitis B vaccine regimens used, together with the EPI vaccines of the Philippines Department of Health. Newborn infants were randomly assigned to receive either regimen 1 or regimen 2 during the first year of the study. During the second year, only regimen 3 was used. The hepatitis B vaccine used was a heat inactivated, plasma derived vaccine given intramuscularly at 1.5 ,ug/kg/dose (0.5 ml/dose). The infants were followed up by the research team at six and 12 months, and, whenever possible, at 24 months. Antibody to HBsAg (anti-HBs), antibody to the core antigen (anti-HBc), and HBsAg were determined by radioimmunoassay.
Using a delivery system provided entirely by staff of the Rural Health Unit in the study area, the coverage rate for fully immunised children ranged from 80-9% to 84% (Table II) . 8 In both bivariate and multivariable analyses, the type of hepatitis B vaccine schedule significantly influenced the anti-HBs response of the immunised infants. The highest anti-HBs seroconversion rate was reported for regimen 1 (88%) and the lowest for regimen 3 (72%) (Table II) . Neither timeliness of administration of hepatitis B vaccines nor storage conditions (intact cold chain versus short storage at room temperature) were found to have a significant effect on the anti-HBs response. In addition, only six (0.48%) of the infants followed up were found to be HBsAg positive. The overall infection rate, as reflected by HBsAg or anti-HBc positivity, or both, in six monthly follow ups, was 2.7% in the first year and 1.6% in the second year.
The study led to the following conclusions: (a) hepatitis B vaccination can be effectively integrated into the EPI schedule; (b) it is feasible to give the first dose of hepatitis B vaccine within the first seven days of life, particularly for hospital deliveries or home births attended by Rural Health Unit midwives; and (c) the various hepatitis B-EPI schedules evaluated achieve good immunogenicity. Since the introduction of various hepatitis B-EPI pilot programmes, a gradual decrease in the prevalence of HBsAg positivity has been observed, both in the Philippines and in other parts of Asia. 8 9 Table III. infection occurring later in life -perhaps during work as an adult CSW -when the probability of progressing to chronic HBsAg carriage is lower than that following infection during infancy and childhood. CSWs in the 'other countries' shown in Table III generally had a lower prevalence of HBsAg positivity and HBV exposure compared with those from endemic countries in Asia. In Japan, Peru, and Mexico, there were no statistically significant differences in HBsAg positivity rates between CSWs and controls. However, the prevalence of other HBV markers was significantly higher in CSWs than in controls,17 19 23 a pattern similar to that seen in Malaysia. In non-endemic countries like Spain, the USA, and Australia, the prevalence of HBV infection was substantially higher in CSWs than in the general population.' The risks associated with intravenous drug use, whether or not the subjects are CSWs, are especially high. Table IV lists the prevalence of HBV infection among IVDUs in different countries.5 15 21 24 28-33 35 In endemic countries in Asia, the prevalence of HBV markers among IVDUs was higher than that in the general population. Interviews with IVDUs in the Philippines showed that single use of 'disposable' syringes was almost unheard of and that injecting paraphernalia were generally cleaned only with alcohol or soap and water.5 In nonendemic countries, although rates for HBV exposure among IVDUs were higher than the general population, they were similar to those found in CSWs. As noted earlier, however, CSWs who were also injecting drug users were twice as likely to be infected with HBV as non-injecting CSWs. As with HIV-1, some of the risk factors associated with hepatitis C virus (HCV) infection are the same as those for HBV infection, particularly intravenous drug use. Both IVDUs and CSWs, therefore, should also be investigated for markers of HCV infection. 30 34 In developed countries, coinfection with HBV and HCV among IVDUs and CSWs is common, while coinfection rates in developing countries can vary considerably. In a survey of Filipino IVDUs, 606% were found to be positive for both anti-HCV and anti-HBc, and 9.6% were positive for anti-HCV, anti-HBc, and HBsAg.5
Among Filipino CSWs surveyed, however, concomitant anti-HCV and anti-HBc positivity was seen in only 6%, and only one of 216 CSWs was also positive for HBsAg.5 This suggests that HBV is more efficiently transmitted through sexual contact than HCV, but that the parenteral route is an important mechanism for both viruses.
Control of HBV infection EDUCATION AND SCREENING
For CSWs and IVDUs, innovative health education and counselling strategies are needed to convey important messages pertaining to safe sex practices, including the use of barrier contraceptives and possible health risks of extravaginal intercourse, and the use and risks of needles and syringes. Drug treatment programmes, including needle exchange schemes have been used with a degree of success in some countries like Australia,22 but have not been uniformly successful elsewhere.30 Screening for sexually transmitted diseases in high risk populations could also help to reduce the incidence of HBV infection in these groups.
Screening for HBV markers, followed by vaccination of seronegative high risk people, has been attempted, again with varying degrees of success.22 30 
Conclusions
The partial implementation of the 'mass' immunisation programme in the Philippines cannot be expected to reduce the burden of infection as impressively and rapidly as in countries like Taiwan and the Gambia, since transmission from unvaccinated infected children will probably persist. If the cost of hepatitis B vaccine matched that of the other immunogens in the EPI, comprehensive control would be more feasible for poorer countries. The control programme would cover, in order of priority: immunisation of newborn infants, an effective blood safety programme, use of disposable needles and syringes, continuing health education of the public (particularly high risk groups), 'catch up' immunisation of older children and other risk groups, and development of secondary prevention strategies for chronically infected people. For these to be achieved, effective partnerships are needed between the public and private sectors participating in hepatitis B control.
